Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours, represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking remains the main risk ...
and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [1]. Unfortunately, the majority of NSCLC patients are diagnosed at advanced stages, resulting in a poor prognosis for these individuals [2,3]. Recently, several carcinogenic...
NSCLC is the most common type of lung cancer, accounting for approximately 85% of the cases. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma as well as large cell carcinoma [7,8,9]. Common cancer treatment approaches include surgery, chemotherapy, and radiation ...
Non-small cell lung cancer (NSCLC) is typically diagnosed at advanced stages, which limits the effectiveness of therapeutic interventions. The present study aimed to explore the role of the newly identified circLIFRSA in the PTEN/AKT signaling pathway an
Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR and Cho WC: Role of autophagy and apoptosis in non‑small-cell lung cancer. Int J Mol Sci 18: 18, 2017.Liu G, Pei F, Yang F, et al. Role of autophagy and apoptosis in non-small-cell ...
A total of 123 cases of advanced non–small cell lung cancer (NSCLC) with confirmed EGFR mutations who received osimertinib monotherapy from 2014 to 2019 at the Osaka International Cancer Institute (Osaka, Japan) were evaluated. Cardiac AEs were defined according to Common Terminology Criteria for ...
New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field....
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarif
BCL2were targeted.This is the first ever genomic study from the region targeting the critical genes involved in the pathophysiology of non-small cell lung cancer. It is noteworthy that such studies will provide the holistic view of genetic landscape of non-small cell lung cancer in population of...